Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583739 | 0.91 | CSF1R (0.46) | ALDH1A1TDP1POLBMAPTSMN1; SMN2 | |
| SCHEMBL16088471 | 0.89 | MAPT (0.49) | ALDH1A1TDP1POLBMAPTSMN1; SMN2 | |
| SCHEMBL4572804 | 0.88 | CSF1R (0.44) | ALDH1A1TDP1POLBMAPTSMN1; SMN2 | |
| SCHEMBL11018264 | 0.86 | CSF1R (0.46) | ALDH1A1HPGDMAPK1TSHRMEN1 | |
| SCHEMBL3526298 | 0.84 | TSHR (0.54) | ALDH1A1TDP1POLBMAPTSMN1; SMN2 | |
| SCHEMBL15205988 | 0.84 | ALDH1A1 (0.53) | ALDH1A1TDP1POLBMAPTSMN1; SMN2 | |
| SCHEMBL6322751 | 0.83 | TSHR (0.53) | ALDH1A1TDP1MAPTSMN1; SMN2HPGD | |
| SCHEMBL3289970 | 0.83 | CSF1R (0.65) | CSF1R | |
| SCHEMBL3293573 | 0.83 | CSF1R (0.44) | ALDH1A1TDP1MAPTSMN1; SMN2HPGD | |
| SCHEMBL16088470 | 0.82 | CSF1R (0.44) | ALDH1A1TDP1MAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012466-B2 | Substituted tricyclic pyrazolo-pyrimidine compounds | ARQULE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012466-B2 | Substituted tricyclic pyrazolo-pyrimidine compounds | ARQULE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| WO-2014164729-A1 | SUBSTITUTED TRICYCLIC PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275023-A1 | Substituted Tricyclic Pyrazolo-Pyrimidine Compounds | ARQULE, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140275023-A1 | Substituted Tricyclic Pyrazolo-Pyrimidine Compounds | ARQULE, INC. | 2014-09-18 | — | — | US | disclosed |
| US-8580244-B2 | Cyclodextrin-based polymers for therapeutics delivery | CERULEAN PHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-7728003-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-01 | — | — | US | disclosed |
| US-7642270-B2 | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-05 | — | — | US | disclosed |
| EP-1945637-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-23 | — | — | EP | disclosed |
| EP-1937681-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-15 | — | — | US | disclosed |
| WO-2008055013-A2 | 5-OXO-5,8 - DIHYDRO - PYRIDO - PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007033232-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007033137-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060578-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2007-03-15 | — | — | US | disclosed |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | US | disclosed |
| EP-0153580-A1 | Naphthyridine antibacterial compounds | ABBOTT LABORATORIES (US) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114007-A1 | 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE | FLT3, FES, ALK | ALDH1A1 3103/4885TDP1 662/4885POLB 2203/4885 |
| US-20140275023-A1 | Substituted Tricyclic Pyrazolo-Pyrimidine Compounds | TYMP, DPYD, TYMS | ALDH1A1 1413/4885TDP1 209/4885POLB 269/4885 |
| US-20070060578-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | ALDH1A1 3735/4885TDP1 974/4885POLB 2020/4885 |
| US-20070060577-A1 | 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase | FLT3, FES, FGR | ALDH1A1 3590/4885TDP1 869/4885POLB 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.